Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects and Mechanism of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension
NCT06055452Phase 4Recruiting
- Sponsor
- National Center for Cardiovascular Disease
- Start
- Jan 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in heart failure (HF) and hypertension (HTN) comparing Empagliflozin with Placebo (2 arms). Primary endpoint: Left Atrial Volume Index at 6 months. Started Jan 2024; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
heart failure (HF)hypertension (HTN)
Beyond the preview
Go deeper on NCT06055452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06055452.